Skip to main
BOLD
BOLD logo

BOLD Stock Forecast & Price Target

BOLD Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Boundless Bio Inc is at the forefront of pioneering therapies for oncogene-amplified tumors, with its innovative ecDTx, BBI-355, showcasing a strong potential to improve treatment efficacy through a toxicity-mitigated dosing strategy. The company's focus on targeting extrachromosomal DNA (ecDNA) aligns with evolving trends toward precision medicine within oncology, positioning the firm advantageously in the market. Additionally, the prospect of successful development of their unexplored technologies could represent significant upside potential that may enhance the company's overall valuation.

Bears say

The outlook on Boundless Bio Inc.'s stock appears negative due to a combination of clinical development risks and therapeutic efficacy concerns surrounding its lead asset, BBI-355. There are significant uncertainties, including potential delays in clinical trials, unfavorable data related to its therapeutic window, and the possibility of not receiving regulatory approval, all of which could impact the company's operational timeline and financial prospects. Additionally, the risks of setbacks in other pipeline programs and a slower-than-anticipated market penetration for BBI-355 further exacerbate concerns regarding medium- to long-term shareholder dilution.

BOLD has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boundless Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boundless Bio Inc (BOLD) Forecast

Analysts have given BOLD a Buy based on their latest research and market trends.

According to 2 analysts, BOLD has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boundless Bio Inc (BOLD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.